Loading clinical trials...
Loading clinical trials...
The primary objective of this phase 1b study is to evaluate the safety and tolerability of blinatumomab and AMG 404 in combination in adults with R/R B-ALL and to estimate the maximum tolerated dose (...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Amgen
NCT07400029 · Acute Lymphoblastic Leukemia
NCT07328503 · Acute Lymphoblastic Leukemia, B-All
NCT02981628 · Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, and more
NCT05579132 · Acute Lymphoblastic Leukemia
NCT06777979 · Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, and more
City of Hope National Medical Center
Duarte, California
University of Chicago
Chicago, Illinois
Icahn School of Medicine at Mount Sinai
New York, New York
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions